Solid organ transplants (kidney, liver, heart) get all the headlines. But stem cell transplants are the fastest‑growing application segment. The US transplantation market forecast shows that stem cell transplantation is growing at over 10% CAGR, driven by CAR‑T cell therapy for blood cancers and cord blood transplants for genetic disorders.

What's new? Haploidentical transplants — using a half‑matched relative as a donor, with post‑transplant chemotherapy to prevent rejection. That expands the donor pool to almost everyone. The US transplantation market analysis notes that the fastest‑growing end‑user segment is transplant centers, which are moving from inpatient to outpatient stem cell transplants — reducing costs and improving quality of life.

But complications remain: graft‑versus‑host disease (GVHD), infections, and relapse. That's why researchers are developing off‑the‑shelf CAR‑T cells from healthy donors — no waiting for manufacturing.

The message: stem cell transplants are no longer a last resort. They're becoming first‑line therapy for many cancers. And with better GVHD prevention, they're safer than ever.